AMRX vs RDY: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: AMRX is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AMRX and RDY share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AMRX and RDY exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Amneal Pharmaceuticals is a Bridgewater, New Jersey based biopharmaceutical company with a portfolio of roughly 300 complex generic, specialty, and biosimilar medicines that fill more than 160 million prescriptions a year, mostly in the United States. The business runs in three segments: Affordable Medicines (retail generics, injectables, and biosimilars, the largest at roughly 58% of revenue), Specialty (branded neurology and endocrinology treatments including Parkinson's disease and migraine, around 17% of revenue), and AvKARE (distribution to US federal, retail, and institutional customers, roughly 25% of revenue).

Full AMRX guide

Dr. Reddy's Laboratories, founded in 1984 and based in Hyderabad, India, is one of the largest Indian pharmaceutical companies, spanning active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars, and over-the-counter products. Its therapeutic focus areas include gastrointestinal, cardiovascular, diabetes, oncology, pain management, and dermatology, and its major markets are the United States, India, Russia and CIS, Europe, and emerging markets. The US generics arm (Dr. Reddy's Laboratories, Inc., based in Princeton, New Jersey) is the single largest revenue contributor, and the company trades on the NYSE as an American Depositary Receipt (ADR) while also listing in India.

Full RDY guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• AMRX drivers: Specialty and biosimilar mix shift; Kashiv BioSciences acquisition.
• RDY drivers: Biosimilars ramp; GLP-1 / semaglutide opportunity.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Amneal carries meaningful leverage, with net debt of roughly $2.5 billion and a net-debt-to-EBITDA ratio near 3.8x, which amplifies both upside and downside and limits financial flexibility. For RDY, the loss of generic Revlimid exclusivity in early 2026 removed a large, high-margin profit stream, and Q4 FY26 showed the impact: revenue fell about 11.6% year over year and gross margin dropped to roughly 44.8% from about 55.6% a year earlier.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick AMRX if you believe its drivers more; RDY if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the AMRX and RDY guides.

AMRX. Amneal reaffirmed 2026 guidance of roughly $3.05 to $3.15 billion in net revenue and about $740 to $770 million in adjusted EBITDA. The stock has traded on a relatively rich earnings multiple versus generics peers, reflecting expectations for its specialty and biosimilar growth. Enterprise value of roughly $7.7 billion sits well above market cap because of the substantial debt load.

RDY. FY2026 (year ended March 31, 2026) revenue was about 335,933 million rupees (roughly $4.0 billion), up about 3.2%, but Q4 profit before tax collapsed to about 2.6% of revenue as the Revlimid exclusivity ended and margins compressed. The stock trades around a mid-20s price-to-earnings multiple with a low payout ratio (near 15%) and a modest sub-1% dividend yield. Figures are approximate, converted from Indian rupee reporting, and can shift with exchange rates and each quarterly release.

Headline figures (approximate, July 2026): AMRX shows revenue (ttm) ~$3.0B, q1 2026 net revenue ~$723M (up ~4% YoY), q1 2026 adjusted ebitda ~$202M (up ~19% YoY), 2026 revenue guidance ~$3.05B to $3.15B; RDY shows revenue (fy26) ~$4.0B, market cap ~$12.8B, p/e (normalized) ~27x, fy26 ebitda margin ~22.8%.

AMRX and RDY are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined AMRX and RDY exposure against your real portfolio. It is not an investment adviser.